Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations

Although endocrine therapy is successfully used to treat patients with estrogen receptor (ER) positive breast cancer, a substantial proportion of this population will relapse. Several mechanisms of acquired resistance have been described including activation of the mTOR pathway, increased activity o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ladd, Brendon, Mazzola, Anne Marie, Bihani, Teeru, Lai, Zhongwu, Bradford, James, Collins, Michael, Barry, Evan, Goeppert, Anne U., Weir, Hazel M., Hearne, Kelly, Renshaw, Jonathan G., Mohseni, Morvarid, Hurt, Elaine, Jalla, Sanjoo, Bao, Haifeng, Hollingsworth, Robert, Reimer, Corinne, Zinda, Michael, Fawell, Stephen, D'Cruz, Celina M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342331/
https://www.ncbi.nlm.nih.gov/pubmed/27472462
http://dx.doi.org/10.18632/oncotarget.10852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342331/
https://www.ncbi.nlm.nih.gov/pubmed/27472462
http://dx.doi.org/10.18632/oncotarget.10852

Ejemplares similares